• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Eiger Begins Enrollment in LIMT-2 Phase 3 Study of Peginterferon Lambda

    21 Dec 2021 //

    PRNEWSWIRE

    Triple drug combination shows promise in Covid-19 treatment

    11 May 2020 //

    CLINICALTRIALSARENA

    Bausch Health initiates VIRAZOLE trial in Covid-19 patients

    15 Apr 2020 //

    CLINICALTRIALSARENA

    Bausch Health begins clinical study in Canada evaluating Virazole in combo

    13 Apr 2020 //

    PHARMABIZ

    Can old drugs take down a new coronavirus?

    13 Mar 2020 //

    C&EN

    Biogen Idec`s Plegridy (Peginterferon beta-1a) Receives Supplemental Approval In US

    12 Jul 2019 //

    AbbVie reports 99% cure rate for pan-genotypic Hep C therapy

    21 Apr 2017 //

    PHARMA TIMES

    Japan Grants Priority Review to AbbVie`s Investigational Regimen

    25 Mar 2017 //

    DDDMAG

    Aviragen takes a tumble as RSV drug fails mid-stage trial

    02 Feb 2017 //

    FIERCE BIOTECH

    SMC OKs four new therapies for NHS use in Scotland

    18 Jan 2017 //

    PHARMATIMES

    Enanta reports positive results from phase 3 CERTAIN-1 study

    11 Jan 2017 //

    PHARMABIZ

    Mylan Signs Sub-license Agreement with the Medicines Patent Pool

    28 Nov 2016 //

    PR NEWSWIRE

    Recent Success in HCV Treatment Brings Relief to Patients

    07 Nov 2016 //

    DRUG DEVELOPMENT

    AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAK

    26 Apr 2016 //

    PR NEWSWIRE

    Merck says its Zepatier showed better efficacy, safety compared with competition

    13 Apr 2016 //

    PHARMAFILE

    Australia bets $1B on pricey hepC drug in broad effort to eradicate the disease

    23 Dec 2015 //

    FIERCE PHARMA

    U.S. FDA approves Gilead`s hepatitis C drug for expanded use

    13 Nov 2015 //

    REUTERS

    AbbVie nears launch of Viekira into crowded Japan HCV battle

    05 Nov 2015 //

    FIERCE PHARMA ASIA

    Merck drug could offer Hep C cure to kidney disease patients

    06 Oct 2015 //

    PHARMATIMES

    AbbVie hepatitis C cocktail succeeds in late-stage study

    25 Jun 2015 //

    REUTERS

    Abbvie Reports Positive Phase 3 Study Results from all-Oral Treatment for Hepatitis C in Japan

    03 Feb 2015 //

    PHARMABIZ

    Valeant Pharmaceuticals North America LLC , Ongoing Class II recall of Virazole (Ribavirin for Inhalation Solution, USP), Sterile Lyophilized For Administration by Aerosol Inhalation Only, Rx only, Contents: Four 6 g vials, 100 mL, Distributed by: Valeant Pharmaceuticals North America, Bridgewater, NJ 08807 USA, NDC 0187-0007-14. because of Non-Sterility: Valeant`s laboratory observed a positive microbial contamination of Virazole lot 340353F, during testing at the 12 month stability pull.

    28 Jan 2015 //

    FDA

    NICE Backs New Hepatitis C Treatments

    16 Jan 2015 //

    PMLIVE

    Valeant Pharmaceuticals North America LLC Issues Voluntary Recall of Virazole® (ribavirin powder for solution) in the United States

    02 Jan 2015 //

    PR NEWSWIRE

    CA Panel: Gilead`s Harvoni Cost-Effective At $95K, But Only Affordable At Half the Price

    15 Dec 2014 //

    FIERCEPHARMA

    Class Action Lawsuit Challenges the Exorbitant Pricing of Gilead`s Hepatitis-C Drug Sovaldi

    09 Dec 2014 //

    PRNEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.